Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-09

Clinical Trial Update: Nesvategrast (OTT166) in Diabetic Retinopathy (DR) [Phase 2]

View source ↗

Summary

Phase 2 trial of Nesvategrast (OTT166) for diabetic retinopathy has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nesvategrast (OTT166) (nesvategrast)

Snippet

Sponsor: OcuTerra Therapeutics, Inc. | Conditions: Diabetic Retinopathy | Phase 2 | Status: COMPLETED | Results posted: 2024-08-09